{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"The number of participants with a documented Complete Response (CR) or better, per International Myeloma Working Group (IMWG) criteria.","groups":[{"description":"Induction Phase: 8 cycles (cycle length of 28 days)\n\n* Daratumumab SC:\n\n  1800mg SC weekly for 8 weeks for Cycle 1 and 2 1800mg SC every 2 weeks on Day 1 and 15 for Cycle 3-6 1800mg SC every 4 weeks on Day 1 for Cycle 7-8\n* Clarithromycin\n\n  500mg PO BID until VGPR or 8 cycles, whichever occurs first\n* Pomalidomide 4mg PO on Days 1-21\n* Dexamethasone 20mg IV as pre-medication on Day 1, 8 40mg PO on the day after daratumumab for Cycle 1 Days 15 and 22 40mg PO pre-daratumumab weekly for Cycle 2-6 20mg PO pre-daratumumab weekly for Cycle 7-8\n\nMaintenance Phase (Cycle 9+): Up to 24 cycles (cycle length of 28 days)\n\n* Daratumumab 1800 mg SC on Day 1\n* Pomalidomide 4mg PO on Day 1-21\n* Dexamethasone 20mg PO pre-daratumumab weekly for Cycles 9 and beyond\n\nDaratumumab SC: Given as 1800mg via injection\n\nClarithromycin: Given as 500mg oral capsule\n\nPomalidomide: Given as 4mg oral capsule\n\nDexamethasone: Given as 20mg IV and 20mg or 40mg oral tablets","id":"OG000","title":"Daratumumab/Clarithromycin/Pomalidomide/Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Approximately 1 year","title":"Complete Response Rate or Better","type":"SECONDARY","unitOfMeasure":"Participants"}